IL1RAP antibodies engineered to block IL1‐signaling and to enhance ADCC activity have shown strong therapeutic effects in patient‐derived chronic myeloid leukemia (CML) and AML xenograft models [53, 54]. The gene discussed is IL1A; the disease is acute myeloid leukemia.